Lucero Bio, a Swedish biotech company developing a technology platform to enable pharmaceutical companies to test 3D cell cultures at scale, has moved into AstraZeneca’s BioVentureHub.
With the trend in healthcare towards personalised medicine, Lucero’s technology – which integrates artificial intelligence, laser optics and microfluidics – addresses the need to develop a better understanding of the underlying mechanistic biology of drug response. This enables pharmaceutical companies to make faster pipeline decisions and accelerate promising candidates to the clinic.
Christopher Jacklin, CEO at Lucero Bio, explains the background behind the company’s move to the BioVentureHub, “We’re joining the BioVentureHub because we are part of a Vinnova-backed research consortium called Nanoscale Drug Testing. AstraZeneca is also a partner in this collaboration, so we wanted to be closer to AstraZeneca’s labs so that we could better facilitate our work together. We also believe that Lucero is aligned with the BioVentureHub’s collaborative approach to innovation within life science. It will be a great place for us to, not only interact with AstraZeneca staff, but also with the other BioVentureHub companies to help each other solve pressing challenges in the industry.”
Thomas Lundbäck, Director of Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, comments, “AstraZeneca has a strong interest in highly miniaturised, disease-relevant cell models, where efficacy and safety in response to treatment can be routinely assessed. Lucero Bio offers an innovative solution for solving this challenge at a scale where it has the potential to replace simpler screening models. We’re really pleased that Chris and his team are joining the BioVentureHub so we can work closely with them in our labs.”
Magnus Björsne, CEO for AstraZeneca’s BioVentureHub, adds, “This is a great example of how the BioVentureHub is catalysing collaborative innovation and creating value for AstraZeneca and emerging companies in the life science ecosystem. Lucero Bio has an exciting multi-disciplinary technology in a scientific area of interest to AstraZeneca. Bringing them closer together through the BioVenturehub is a win-win with the potential to drive advancements within the life science industry.”
For more information, please see this short video interview with Christopher Jacklin, CEO at Lucero Bio, and Pernilla Isberg, COO at AstraZeneca’s BioVentureHub:
Author: Jamie Smith